Researchtirzepatideglp-1finerenonechronic kidney diseasetype 2 diabetes

GLP-1 and tirzepatide beat finerenone on kidney outcomes in TriNetX cohort

Incretin initiators had a hazard ratio of 0.71 for end-stage kidney disease, dialysis or stage 5 CKD, though absolute risk difference was not significant.

By Priya Raman · Science Reporter

Oct 6 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01Retrospective TriNetX study matched 4554 adults with type 2 diabetes and stage 3-4 CKD initiating GLP-1 or GLP-1/GIP receptor agonists versus finerenone, July 2021 to November 2025; the composite endpoint occurred in 4.8% versus 6.0%.
02Total eGFR slope favoured incretins by 1.04 mL/min/1.73m2/year, but the chronic slope from 0.5 to 2.5 years showed no difference, tempering claims of sustained kidney protection.
03Baseline albuminuria was missing for most participants, so residual confounding is possible; the authors say findings apply to this specific matched population.

From the source

Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study
Diabetes, obesity & metabolism · 2026 Oct 7 · Sehtman-Shachar DR, Fishkin A, Leibowitz G et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42842950/